PLEASANTON, Calif., April 17 /PRNewswire/ -- MicroFluidic Systems (MFSI), a privately-held company, announced today that they have been awarded a Phase II continuation of its Bioagent Autonomous Networked Detector (BAND) System development contract by the Department of Homeland Security’s (DHS) Homeland Security Advanced Research Projects Agency (HSARPA). This Phase II continuation program is to produce manufacturing prototypes of the proof-of- principal systems developed in the Phase I contract over the past 18 months at MFSI. Phase II will lead to the third level of development (Phase III) where additional systems will be built for testing as potential replacements for the nation’s current BioWatch program. Coupled with its additional on-going contract with HSARPA for the development of an instantaneous bioaerosol detection system and its stand-alone laboratory sample processing instruments including the BioLyser(TM), MFSI continues to offer a variety of solutions to biological agent detection. Applications for these technologies go beyond homeland security and biodefense, to areas such as clinical diagnostics, emerging disease monitoring, industrial testing, forensics, and research.
“We welcome the opportunity to continue this important work for DHS,” commented Dr. M. Allen Northrup, MFSI President and CEO. “This represents a huge business and growth opportunity for MFSI,” he added.
MicroFluidic Systems Inc. (MFSI) was founded in 2001 and is focused on the development of microfluidic systems for automated preparation of biological assays. MFSI personnel have been involved with the development of automated DNA-based pathogen detection systems and microfluidics for the US Government and commercial markets for over 12 years, including the world’s first miniaturized, portable, battery-operated, real-time, polymerase-chain-reaction (PCR)-based detection system. For more information, please contact MFSI at 925-600-9026 or visit the website, www.mfsi.biz.
Statements in this press release are forward-looking. Actual results might differ from these statements due to unforeseen events and uncertainties. MFSI disclaims any intention to or obligation to update these forward-looking statements.
MicroFluidic Systems Inc.
CONTACT: MicroFluidic Systems, +1-925-600-9026
Web site: http://www.mfsi.biz/
